Shanghai Jemincare Pharmaceutical Co. Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has identified androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism, polycystic ovary syndrome, precocious puberty, spinal and bulbar muscle atrophy, and age-related macular degeneration.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed phosphorus-containing compounds acting as androgen receptor antagonists reported to be useful for the treatment of cancer, alopecia, acne, hirsutism and more.
Shanghai Jemincare Pharmaceuticals Co. Ltd. has disclosed nitrogen-containing heterocyclic compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors potentially useful for the treatment of cancer.
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
Ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors have been reported by Shanghai Jemincare Pharmaceuticals Co. Ltd. to be potentially useful for the treatment of cancer, fibrosis, inflammation, pain, neurodegeneration, autoimmune, metabolic and cardiovascular disorders, among others.
Shanghai Jemincare Pharmaceuticals Co. Ltd. and Jiangxi Jemincare Group Co. Ltd. have patented compounds reported to be useful for the treatment of fungal infections.
Jiangxi Jemincare Group Co. Ltd. and Shanghai Jemincare Pharmaceuticals Co. Ltd. have divulged tricyclic hypoxia inducible factor 2-alpha (HIF-2-alpha; EPAS1) inhibitors reported to be useful for the treatment of cancer, von Hippel-Lindau disease, pulmonary hypertension and inflammatory bowel disease.
